FIELD: medicine.
SUBSTANCE: method is implemented by using 9-dialkyl aminoethyl-2-(4-fluorophenyl)imidazo[1,2-a]-benzimidazole dihydrochloride of general formula I
, wherein a) NR2 = pyrrolidino; b) NR2 = morpholino as an agent possessing anticonvulsant activity. The compound may be used for preparing an anticonvulsant.
EFFECT: higher anticonvulsant activity.
2 cl, 8 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTISPASMODIC MEDICATION | 2014 |
|
RU2568841C1 |
| PHARMACEUTICAL COMPOSITION WITH ANALGESIC ACTIVITY IN INJECTION FORM (VERSIONS) | 2013 |
|
RU2563211C2 |
| 1-(3-MORPHOLINOPROPYL)-2-PHENYLIMIDAZO[1,2-a]-BENZIMIDAZOLE DIHYDROCHLORIDE, HAVING PURINE P2Y-RECEPTOR ANTAGONIST PROPERTIES, ANTIAGGREGANT AND ANTITHROMBOTIC ACTIVITY | 2008 |
|
RU2391345C2 |
| AGENT SHOWING SEROTONIN 5-HT-RECEPTOR ANTAGONIST PROPERTIES | 2010 |
|
RU2438669C1 |
| KAPPA-OPIOID AGONIST | 2009 |
|
RU2413512C1 |
| PHARMACEUTICAL COMPOSITION IN SOLID FORM WITH ANALGESIC ACTIVITY | 2013 |
|
RU2545861C1 |
| ANTITHROMBOTIC AGENT AFFECTING REGULATION OF THROMBOCYTE CAPACITY | 2008 |
|
RU2377990C1 |
| METHOD FOR PREDICTING THE UNFAVORABLE COURSE OF EPILEPSY IN CHILDREN IN THE FIRST YEAR OF LIFE | 2022 |
|
RU2787512C1 |
| METHOD FOR DIAGNOSING NEUROIMMUNE DISORDERS IN YOUNG CHILDREN WITH EPILEPSY | 2021 |
|
RU2767271C1 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING PAROXYSMAL CONDITIONS | 2011 |
|
RU2469722C1 |
Authors
Dates
2016-01-20—Published
2014-09-19—Filed